Apop is attending the Bio International Convention in San Diego, June 3-6 2024
Apop’s breakthrough technologies are transforming our knowledge of complex cell stress mechanisms (apoptosis and autophagy) associated with serious diseases.
Apop's first commercial product range is a pipeline of proprietary novel imaging reagents . All Apop products are based on our proprietary calcitonin receptor monoclonal antibody technology, CalRexin® that targets a novel extracellular marker of these complex processes and backed by multiple scientific publications .
CalRexin® imaging reagents are first-in-class products that deliver high-fidelity data to meet a growing demand for more effective tools to detect and monitor cell stress events such as autophagy and apoptosis.
The dysregulation of these critical cellular pathways are associated with diseases such as neurodegeneration, cancer, and pathogenic infections. CalRexin® imaging reagents are available in a range of monoclonal antibody: fluorophore conjugates to detect apoptosis (death) and autophagy in cells that are cultured.
CalRexin®:Autophagy imaging reagent
The upcoming CalRexin®:Autophagy imaging reagent stands out as a significant technical advancement in primary screening of chemical libraries on high-throughput or high-content platforms for novel modulators of autophagy. Unlike alternatives, it identifies sequential structures of the autophagy pathway from early endosomes to autolysosomes, resists photobleaching and is extremely stable, properties that are essential for multiple imaging of live cells on high-throughput analyzers for researchers, bio-pharma and diagnostic companies.
CalRexin® proprietary imaging reagents: CalRexin®:488, CalRexin®:568, CalRexin®:647, CalRexin®:680
Apop’s suite of proprietary CalRexin® imaging reagents target the Calcitonin receptor, a novel marker of PCD. CalRexin® imaging reagents can be readily incorporated into standard workflows such as flow cytometry, are able to identify sub-populations of stressed (dying) cells and provide exceptional image clarity of cells undergoing autophagy and apoptosis, just two of the processes associated with PCD identified so far. CalRexin® can be utilized for live cell assays and unlike alternatives, are stable without the spectre of false positives.
The Apop cell stress/PCD imaging product range is being followed by a range of emerging therapeutics, and diagnostics products that are under development:
Therapeutics and diagnostics - early stage of development
A therapeutic target (ADC/Antibody:immunotoxin) for treatment of one of the most recalcitrant cancers, Glioblastoma Multiforme is also currently under development with two globally recognized universities in Australia and Germany. The third platform technology for CalRexin® is for sensitive imaging of PCD in patients and whole organisms, eg: PET scanning.
For further information, contact Elpis Baron